University of Hawaii Cancer Center CCSG
夏威夷大学癌症中心 CCSG
基本信息
- 批准号:10837568
- 负责人:
- 金额:$ 219.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-05 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAnalytical BiochemistryAppointmentAuthorization documentationBioinformaticsBiometryBudgetsCancer BiologyCancer BurdenCancer CenterCancer Center Support GrantCancer ControlCancer EtiologyCancer Research ProjectCatchment AreaCharacteristicsClinicalClinical ResearchClinical TrialsCollaborationsCommunitiesCommunity Health EducationCommunity NetworksCommunity OutreachCommunity TrialEducationEnvironmentEthnic OriginEvaluationFacultyFaculty RecruitmentFinancial SupportFoundationsFundingGenomicsGoalsGuamHawaiiHealth systemInfrastructureInterventionIntervention TrialInvestigationInvestmentsMalignant NeoplasmsMedicalMissionNative HawaiianNatural ResourcesNetwork-basedPatient CarePeer ReviewPoliciesPopulationPopulation SciencesPrevention trialProcessPublic HealthPublic Health PracticePublicationsResearchResource SharingRisk AssessmentScienceStatutes and LawsStrategic PlanningTranslatingUniversitiesanticancer researchauthoritycancer clinical trialcancer health disparitycancer preventioncancer riskcancer therapycommunity engagementdrug discoveryethnic diversityhealth care deliveryinter-institutionalmembermetabolomicsnovelnutritionoperationpopulation basedprogramsrecruitsquare foot
项目摘要
ABSTRACT
The mission of the University of Hawai‘i Cancer Center (UHCC) is to reduce the burden of cancer through
research, education, patient care and community outreach with an emphasis on the unique ethnic, cultural and
environmental characteristics of Hawai‘i and the Pacific. To accomplish this mission, UHCC is organized into
two cancer research programs: Population Sciences in the Pacific (PSP) and Cancer Biology (CB).
Programs are each organized with two components spanning the study of basic mechanism and etiologies of
cancer to addressing targets and interventions in order to translate discovery to the population it serves. Within
its programs, UHCC has a strong foundation of cancer research with over $15 million in peer-reviewed funding,
68% of which is from the NCI. PSP has 24 full members and CB has 18 full members who are highly
collaborative as evidenced by a high percentage of intra- and inter-programmatic, and inter-institutional, research
collaborations and publications. To facilitate successful attainment of research goals, UHCC supports five
shared resources: Biostatistics, Genomics and Bioinformatics, Analytical Biochemistry, Nutrition
Support, and Metabolomics. UHCC serves a unique ethnically diverse catchment area in Hawai‘i and the
Pacific and a unique environment rich in natural resources. This drives UHCC’s focus on ethnic diversity and
cancer and research and community engagement directed toward addressing significant cancer health
disparities among specific populations, including Native Hawaiians. Research programs, community education,
public health and clinical trial interventions are targeted toward cancers of importance in the catchment area and
basic investigations include evaluation of compounds from the environment for drug discovery research. A
unique, community-network based clinical research enterprise has been established through which UHCC
provides access to cancer clinical trials for over 70% of the Hawai‘i population; this is supported in part by a
UHCC-led affiliation of three competing health systems as a cooperative venture supporting UHCC. Cancer
prevention activities across the Pacific, in collaboration with the University of Guam and others, have had major
impact on cancer control and have led to the formation of the UHCC-led Trans-Pacific Partnership for Cancer
Prevention. The importance of UHCC in the region is exemplified by its significant impact on cancer control
legislation and State cancer policy. The University of Hawai‘i (UH) has made significant investments in UHCC.
With the recruitment new Director, UH reaffirmed the Director’s direct authority over faculty appointments and
affairs, Center budget and operations, and space allocation in the 187,000 sq. ft. Cancer Center building. The
University, Governor and State have provided increased financial support for operations and authorized
numerous faculty recruitments to strengthen existing programs and embark on new initiatives informed through
the UHCC strategic planning process in support of its mission to reduce the burden of cancer.
摘要
项目成果
期刊论文数量(798)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Diet Quality of Young Children in the US-Affiliated Pacific's Children's Healthy Living (CHL) Program.
美国附属太平洋儿童健康生活 (CHL) 计划中幼儿的饮食质量。
- DOI:10.1016/j.jand.2023.08.003
- 发表时间:2023
- 期刊:
- 影响因子:4.8
- 作者:DelaCruz,Rica;Novotny,Rachel;Wilkens,LynneR;Shvetsov,YuriiB;Yamanaka,AshleyB;Butel,Jean;Aflague,TanishaF;Coleman,Patricia;Shallcross,Leslie;Deenik,Jonathan;Mapa,VictoriaLeeR;Boushey,CarolJ;Fleming,Travis
- 通讯作者:Fleming,Travis
Cholangiocarcinoma in Pacific Islanders Compared to Asians.
太平洋岛民的胆管癌与亚洲人的比较。
- DOI:
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Shiosaki,JessicaR;Sempokuya,Tomoki;Hernandez,BrendaY;Wong,LindaL
- 通讯作者:Wong,LindaL
A Dietary Supplement Frequency Questionnaire Correctly Ranks Nutrient Intakes in US Older Adults When Compared to a Comprehensive Dietary Supplement Inventory.
与综合膳食补充剂清单相比,膳食补充剂频率调查问卷正确地对美国老年人的营养摄入量进行了排名。
- DOI:10.1093/jn/nxab140
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Steffen,AlanaD;Wilkens,LynneR;Yonemori,KimM;Albright,CherylL;Murphy,SuzanneP
- 通讯作者:Murphy,SuzanneP
E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies.
- DOI:10.1183/13993003.01815-2019
- 发表时间:2021-01
- 期刊:
- 影响因子:0
- 作者:Wills TA;Soneji SS;Choi K;Jaspers I;Tam EK
- 通讯作者:Tam EK
cis-Expression QTL analysis of established colorectal cancer risk variants in colon tumors and adjacent normal tissue.
- DOI:10.1371/journal.pone.0030477
- 发表时间:2012
- 期刊:
- 影响因子:3.7
- 作者:Loo LW;Cheng I;Tiirikainen M;Lum-Jones A;Seifried A;Dunklee LM;Church JM;Gryfe R;Weisenberger DJ;Haile RW;Gallinger S;Duggan DJ;Thibodeau SN;Casey G;Le Marchand L
- 通讯作者:Le Marchand L
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Naoto T Ueno其他文献
Navigating the androgen receptor landscape in triple-negative breast cancer
在三阴性乳腺癌中探索雄激素受体领域
- DOI:
10.1016/s1470-2045(25)00029-4 - 发表时间:
2025-03-01 - 期刊:
- 影响因子:35.900
- 作者:
Nithya Sridhar;Naoto T Ueno - 通讯作者:
Naoto T Ueno
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer.
III 期炎性乳腺癌 1 线与 2-3 线新辅助治疗后的临床结果。
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:3.8
- 作者:
F. Nakhlis;Samuel M. Niman;Naoto T Ueno;Elizabeth Troll;Sean J. Ryan;E. Yeh;Laura Warren;J. Bellon;Beth Harrison;T. Iwase;H. T. Carisa Le;S. Saleem;M. Teshome;Gary J. Whitman;Wendy A Woodward;Beth Overmoyer;S. Tolaney;M. Regan;F. Lynce;R. Layman - 通讯作者:
R. Layman
Naoto T Ueno的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Naoto T Ueno', 18)}}的其他基金
Developing a novel combination immunotherapy for triple-negative breast cancer
开发针对三阴性乳腺癌的新型联合免疫疗法
- 批准号:
10734197 - 财政年份:2023
- 资助金额:
$ 219.1万 - 项目类别:
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
开发针对炎性乳腺癌肿瘤微环境的新疗法
- 批准号:
10836263 - 财政年份:2022
- 资助金额:
$ 219.1万 - 项目类别:
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
开发针对炎性乳腺癌肿瘤微环境的新疗法
- 批准号:
10390676 - 财政年份:2022
- 资助金额:
$ 219.1万 - 项目类别:
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
- 批准号:
8146139 - 财政年份:2007
- 资助金额:
$ 219.1万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
8265321 - 财政年份:2007
- 资助金额:
$ 219.1万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7630446 - 财政年份:2007
- 资助金额:
$ 219.1万 - 项目类别:
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
- 批准号:
7500877 - 财政年份:2007
- 资助金额:
$ 219.1万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7252750 - 财政年份:2007
- 资助金额:
$ 219.1万 - 项目类别:
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
乳腺癌中 EGFR 抑制剂厄洛替尼敏感的标志物
- 批准号:
7462422 - 财政年份:2007
- 资助金额:
$ 219.1万 - 项目类别:
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
开发 PEA 15 作为卵巢癌靶向治疗基因
- 批准号:
7894611 - 财政年份:2007
- 资助金额:
$ 219.1万 - 项目类别:
相似海外基金
Research Assistant Analytical Biochemistry
研究助理分析生物化学
- 批准号:
531673-2018 - 财政年份:2018
- 资助金额:
$ 219.1万 - 项目类别:
Experience Awards (previously Industrial Undergraduate Student Research Awards)
Research Assistant Analytical Biochemistry
研究助理分析生物化学
- 批准号:
513242-2017 - 财政年份:2017
- 资助金额:
$ 219.1万 - 项目类别:
Experience Awards (previously Industrial Undergraduate Student Research Awards)
Research Assistant Analytical Biochemistry
研究助理分析生物化学
- 批准号:
515588-2017 - 财政年份:2017
- 资助金额:
$ 219.1万 - 项目类别:
Experience Awards (previously Industrial Undergraduate Student Research Awards)
Research Assistant Analytical Biochemistry
研究助理分析生物化学
- 批准号:
501457-2016 - 财政年份:2016
- 资助金额:
$ 219.1万 - 项目类别:
Experience Awards (previously Industrial Undergraduate Student Research Awards)
Research Assistant Analytical Biochemistry
研究助理分析生物化学
- 批准号:
486575-2015 - 财政年份:2015
- 资助金额:
$ 219.1万 - 项目类别:
Experience Awards (previously Industrial Undergraduate Student Research Awards)